Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
basimglurant + carbamazepine
- Development stage
- Unknown
- Lead developer
- Noema Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**basimglurant + carbamazepine** is an experimental drug combination consisting of basimglurant (INN: basimglurant, development code names RO4917523, RG-7090) and carbamazepine. Basimglurant is a selective negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5). It was developed by Roche and Chugai Pharmaceutical as a potential adjunctive therapy for treatment-resistant depression and fragile X syndrome, with its primary mechanism being the inhibition of mGlu5-mediated glutamatergic signaling. Carbamazepine is a voltage-gated sodium channel blocker widely used as an anticonvulsant, mood stabilizer, and analgesic for trigeminal neuralgia. The combination has been studied in healthy volunteers to assess pharmacokinetic interactions, with carbamazepine known to induce hepatic enzymes that can accelerate the metabolism of other drugs, including potential interactions with basimglurant[1][2][5][8].
- Other names
- basimglurant + carbamazepine
02
Targets
CYP1A2 (Cytochrome P450 1A2)GRM5 (Metabotropic glutamate receptor 5)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on basimglurant + carbamazepine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on basimglurant + carbamazepine.